Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission

Table 1

Inclusion criteria for eligibility and demographic and clinical characteristics of patients previously treated (n = 78).

Radical operation for cancer and completely recovered from operation
No cancer therapy within 30 days
No use of supplements
No severe organ dysfunction
Age 20–80
Written informed consent
Number of patients	78
Age (year)
Mean ± standard deviation	65.6 ± 10.3
Range	29−79
Gender (Male/Female)	46/32
Diagnosis	Number of patients
Prostate cancer (early/advance)	38 (38/0)
Endometrial cancer (early/advance)	12 (8/4)
Bladder cancer (early/advance)	8 (6/2)
Ovarian cancer (early/advance)	6 (3/3)
Cervical cancer (early/advance)	6 (3/3)
Gastric cancer (early/advance)	2 (2/0)
Others (number of patients) (early/advance)	6 (2/4)
Endometrial stromal sarcoma (1), uterine  sarcoma (1), vaginal cancer (1), oral cavity  cancer (1),
Breast cancer (1), renal cell carcinoma (1)
Previous treatment	Number of patients
Operation	57
Chemotherapy	19
Radiotherapy	30